Abstract

Diabetes mellitus (DM) is not a single disease, but a group of diseases that are characterized by chronic hyperglycemia and risk of damage to tissues and organs. The mechanisms of its development are different and due mainly to disorders of insulin secretion or its effects. For this reason, 4 types of DM have been distinguished. One of them is a specific type of DM, determined, inter alia, by the use of certain psychotropic medications. Chronic hyperglycemia often occurs in association with some of these drugs, but in many cases it is categorized erroneously as type 2 (T2DM) or 1 (T1DM). The relationship between DM and psychiatric disorders is bi-directional, involving two mutually independent risk factors for the development of the disease. However, not all patients with a mental illness develop carbohydrate metabolism disorders, which is due to a varied diabetogenic potential and mechanisms of action of psychotropic medications. In clinical practice, questions concerning the frequency of this type of DM, risk factors of its development and hyperglycemic mechanism of psychotropic medications arise. Therefore, the aim of this article is to attempt to answer these questions. From a practical point of view, obtaining such information should allow for the development of appropriate diagnostic and therapeutic procedures.

References

• 1. Al-Atram A.A.: A review of the bidirectional relationship betweenpsychiatric disorders and diabetes mellitus. Neurosciences, 2018; 23:91-96
  Google Scholar
• 2. Al-Janabi I., Arranz M.J., Blakemore A.I., Saiz P.A., Susce M.T., GlaserP.E., Clark D., de Leon J.: Association study of serotonergic genevariants with antipsychotic-induced adverse reactions. Psychiatr.Genet., 2009; 19: 305-311
  Google Scholar
• 3. American Diabetes Association: 2. Classification and diagnosis ofdiabetes: Standards of medical care in diabetes – 2020. Diabetes Care,2020; 43: S14-S31
  Google Scholar
• 4. Aprahamian I., Santos F.S., dos Santos B., Talib L., Diniz B.S.,Radanovic M., Gattaz W.F., Forlenza O.V.: Long-term, low-dose lithiumtreatment does not impair renal function in the elderly: A 2-yearrandomized, placebo-controlled trial followed by single-blind extension.J. Clin. Psychiatry, 2014; 75: e672-e678
  Google Scholar
• 5. Best L., Yates A.P., Reynolds G.P.: Actions of antipsychotic drugson pancreatic β-cell function: Contrasting effects of clozapine andhaloperidol. J. Psychopharmacol., 2005; 19: 597-601
  Google Scholar
• 6. Blonde L., Kan H.J., Gutterman E.M., L’Italien G.J., Kim M.S., HanssensL., McQuade R.D.: Predicted risk of diabetes and coronary heartdisease in patients with schizophrenia: Aripiprazole versus standardof care. J. Clin. Psychiatry, 2008; 69: 741-748
  Google Scholar
• 7. Burcu M., Zito J.M., Safer D.J., Magder L.S., dosReis S., Shaya F.T.,Rosenthal G.L.: Concomitant use of atypical antipsychotics with otherpsychotropic medication classes and the risk of type 2 diabetes mellitus.J. Am. Acad. Child Adolesc. Psychiatry, 2017; 56: 642-651
  Google Scholar
• 8. Burghardt K.J., Seyoum B., Mallisho A., Burghardt P.R., KowluruR.A., Yi Z.: Atypical antipsychotics, insulin resistance and weight; ameta-analysis of healthy volunteer studies. Prog. Neuropsychopharmacol.Biol. Psychiatry, 2018; 83: 55-63
  Google Scholar
• 9. Chebane L., Tavassoli N., Bagheri H., Montastruc J.L., Centres Régionauxde Pharmacovigilance Français: Drug-induced hyperglycemia:A study in the French pharmacovigilance database. Therapie,2010; 65: 447-458
  Google Scholar
• 10. Chen J., Huang X.F., Shao R., Chen C., Deng C.: Molecular mechanismsof antipsychotic drug-induced diabetes. Front. Neurosci., 2017;11: 643
  Google Scholar
• 11. Clark D., Skrobot O.A., Adebiyi I., Susce M.T., de Leon J., BlakemoreA.F., Arranz M.J.: Apolipoprotein-E gene variants associated with cardiovascularrisk factors in antipsychotic recipients. Eur. Psychiatry,2009; 24: 456-463
  Google Scholar
• 12. Das-Munshi J., Ashworth M., Dewey M.E., Gaughran F., Hull S.,Morgan C., Nazroo J., Petersen I., Schofield P., Stewart R., ThornicroftG., Prince M.J.: Type 2 diabetes mellitus in people with severe mentalillness: Inequalities by ethnicity and age. Cross-sectional analysis of 588 408 records from the UK. Diabet. Med., 2017; 34: 916-924
  Google Scholar
• 13. De Hert M., Mittoux A., He Y., Peuskens J.: Metabolic parameters inthe short- and long-term treatment of schizophrenia with sertindoleor risperidone. Eur. Arch. Psychiatry Clin. Neurosci., 2011; 261: 231-239
  Google Scholar
• 14. Erickson S.C., Le L., Zakharyan A., Stockl K.M., Harada A.S., BorsonS., Ramsey S.D., Curtis B.: New-onset treatment-dependent diabetesmellitus and hyperlipidemia associated with atypical antipsychoticuse in older adults without schizophrenia or bipolar disorder. J. Am.Geriatr. Soc., 2012; 60: 474-479
  Google Scholar
• 15. Fathallah N., Slim R., Larif S., Hmouda H., Ben Salem C.: Druginducedhyperglycaemia and diabetes. Drug Saf., 2015; 38: 1153-1168
  Google Scholar
• 16. Feng S., Melkersson K.: Metabolic parameters and long-termantipsychotic treatment: A comparison between patients treatedwith clozapine or olanzapine. Neuro. Endocrinol. Lett., 2012; 33:493-498
  Google Scholar
• 17. Findling R.L., Pathak S., Earley W.R., Liu S., DelBello M.P.: Efficacyand safety of extended-release quetiapine fumarate in youth with bipolardepression: An 8 week, double-blind, placebo-controlled trial. J.Child Adolesc. Psychopharmacol., 2014; 24: 325-335
  Google Scholar
• 18. Foley D., Mackinnon A., Morgan V.A., Watts G.F., Castle D.J., WaterreusA., Galletly C.A.: Effect of age, family history of diabetes andantipsychotic drug treatment on risk of diabetes in people with psychosis:A population-based cross-sectional study. Lancet Psychiatry,2015; 2: 1092-1098
  Google Scholar
• 19. Foley D.L., Mackinnon A., Morgan V.A., Watts G.F., Castle D.J., WaterreusA., Galletly C.A.: Awareness of pre-diabetes or diabetes andassociated factors in people with psychosis. Schizophr. Bull., 2016;42: 1280-1289
  Google Scholar
• 20. Haleem D.J., Sheikh S., Fawad A., Haleem M.A.: Fasting leptin andglucose in normal weight, over weight and obese men and womendiabetes patients with and without clinical depression. Metab. BrainDis., 2017; 32: 757-764
  Google Scholar
• 21. Hardy T.A., Henry R.R., Forrester T.D., Kryzhanovskaya L.A., CampbellG.M., Marks D.M., Mudaliar S.: Impact of olanzapine or risperidonetreatment on insulin sensitivity in schizophrenia or schizoaffectivedisorder. Diabetes Obes. Metab., 2011; 13: 726-735
  Google Scholar
• 22. Henderson D.C., Cagliero E., Gray C., Nasrallah R.A., Hayden D.L.,Schoenfeld D.A., Goff D.C.: Clozapine, diabetes mellitus, weight gain,and lipid abnormalities: A five-year naturalistic study. Am. J. Psychiatry,2000; 157: 975-981
  Google Scholar
• 23. Hermida O.G., Fontela T., Ghiglione M., Uttenthal L.O.: Effect oflithium on plasma glucose, insulin and glucagon in normal and streptozotocin-diabetic rats: Role of glucagon in the hyperglycaemic response.Br. J. Pharmacol., 1994; 111: 861-865
  Google Scholar
• 24. Holt R.I., Mitchell A.J.: Diabetes mellitus and severe mental illness:Mechanisms and clinical implications. Nat. Rev. Endocrinol.,2015; 11: 79-89
  Google Scholar
• 25. Jain V., Patel R.K., Kapadia Z., Galiveeti S., Banerji M., Hope L.:Drugs and hyperglycemia: A practical guide. Maturitas, 2017; 104:80-83
  Google Scholar
• 26. Kharroubi A.T., Darwish H.M.: Diabetes mellitus: The epidemic ofthe century. World J. Diabetes, 2015; 6: 850-867
  Google Scholar
• 27. Kopf D., Gilles M., Paslakis G., Medlin F., Lederbogen F., Lehnert H.,Deuschle M.: Insulin secretion and sensitivity after single-dose amisulpride,olanzapine or placebo in young male subjects: Double blind,cross-over glucose clamp study. Pharmacopsychiatry, 2012; 45: 223-228
  Google Scholar
• 28. Létourneau G., Abdel-Baki A., Dubreucq S., Mahone M., GrangerB.: Hyperosmolar hyperglycemic state associated with ziprasidonetreatment: A case report. J. Clin. Psychopharmacol., 2011; 31: 671-673
  Google Scholar
• 29. Lee H., Song D.H., Kwon J.W., Han E., Chang M.J., Kang H.Y.: Assessingthe risk of type 2 diabetes mellitus among children and adolescentswith psychiatric disorders treated with atypical antipsychotics:A population-based nested case-control study. Eur. Child Adolesc.Psychiatry, 2018; 27: 1321-1334
  Google Scholar
• 30. Lieberman J.A., First M.B.: Psychotic disorders. N. Engl. J. Med.,2018; 379: 270-280
  Google Scholar
• 31. Mackin P., Bishop D., Watkinson H.M., Ferrier I.N.: A prospectivestudy of glycaemic status in anti-psychotic-treated patients. J. Psychopharmacol.,2008; 22: 563-566
  Google Scholar
• 32. Mamakou V., Hackinger S., Zengini E., Tsompanaki E., Marouli E.,Serfatinidis I., Prins B., Karabela A., Glezou E., Southam L., Rayner N.W.,Kuchenbaecker K., Lamnissou K., Kontaxakis V., Dedoussis G., et al.:Combination therapy as a potential risk factor for the developmentof type 2 diabetes in patients with schizophrenia: The GOMAP study.BMC Psychiatry, 2018; 18: 249
  Google Scholar
• 33. McDonnell D.P., Kryzhanovskaya L.A., Zhao F., Detke H.C., FeldmanP.D.: Comparison of metabolic changes in patients with schizophreniaduring randomized treatment with intramuscular olanzapinelong-acting injection versus oral olanzapine. Hum. Psychopharmacol.,2011; 26: 422-433
  Google Scholar
• 34. Melkersson K.I., Scordo M.G., Gunes A., Dahl M.L.: Impact of CYP1A2and CYP2D6 polymorphisms on drug metabolism and on insulinand lipid elevations and insulin resistance in clozapine-treatedpatients. J. Clin. Psychiatry, 2007; 68: 697-704
  Google Scholar
• 35. Moreno-Küstner B., Martín C., Pastor L.: Prevalence of psychoticdisorders and its association with methodological issues. A systematicreview and meta-analyses. PLoS One, 2018;13: e0195687
  Google Scholar
• 36. Nuevo R., Chatterji S., Fraguas D., Verdes E., Naidoo N., ArangoC., Ayuso-Mateos J.L.: Increased risk of diabetes mellitus among personswith psychotic symptoms: Results from the WHO World HealthSurvey. J. Clin. Psychiatry, 2011; 72: 1592-1599
  Google Scholar
• 37. Pisano S., Coppola G., Catone G., Carotenuto M., Iuliano R.,D’Espovito V., Cabaro S., Miraglia Del Giudice E., Bravaccio C., FormisanoP.: Differences in metabolic factors between antipsychotic-inducedweight gain and non-pharmacological obesity in youths. Clin.Drug Invest., 2018; 38: 457-462
  Google Scholar
• 38. Ragguett R.M., Hahn M., Messina G., Chieffi S., Monda M., De LucaV.: Association between antipsychotic treatment and leptin levelsacross multiple psychiatric populations: An updated meta-analysis.Hum. Psychopharmacol., 2017; 32: e2631
  Google Scholar
• 39. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., UnwinN., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., ShawJ.E., Bright D., Williams R., IDF Diabetes Atlas Committee: Global andregional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes FederationDiabetes Atlas, 9th edition. Diabetes Res Clin Pract., 2019; 157: 107843
  Google Scholar
• 40. Salvi V., Grua I., Cerveri G., Mencacci C., Barone-Adesi F.: The riskof new-onset diabetes in antidepressant users – A systematic reviewand meta-analysis. PLoS One, 2017; 12: e0182088
  Google Scholar
• 41. Siafis S., Papazisis G.: Detecting a potential safety signal of antidepressantsand type 2 diabetes: A pharmacovigilance-pharmacodynamicstudy. Br. J. Clin. Pharmacol., 2018; 84: 2405-2414
  Google Scholar
• 42. Srisawasdi P., Vanwong N., Hongkaew Y., Puangpetch A., VanavananS., Intachak B., Ngamsamut N., Limsila P., Sukasem C., Kroll M.H.:Impact of risperidone on leptin and insulin in children and adolescentswith autistic spectrum disorders. Clin. Biochem., 2017; 50: 678-685
  Google Scholar
• 43. Stroup T.S., Byerly M.J., Nasrallah H.A., Ray N., Khan A.Y., LambertiJ.S., Glick I.D., Steinbook R.M., McEvoy J.P., Hamer R.M.: Effectsof switching from olanzapine, quetiapine, and risperidone to aripiprazoleon 10-year coronary heart disease risk and metabolic syndromestatus: Results from a randomized controlled trial. Schizoph. Res.,2013; 146: 190-195
  Google Scholar
• 44. Sylvia L.G., Shelton R.C., Kemp D.E., Bernstein E.E., Friedman E.S.,Brody B.D., McElroy S.L., Singh V., Tohen M., Bowden C.L., Ketter T.A.,Deckersbach T., Thase M.E., Reilly-Harrington N.A., Nierenberg A.A., etal.: Medical burden in bipolar disorder: Findings from the Clinical andHealth Outcomes Initiative in Comparative Effectiveness for BipolarDisorder study (Bipolar CHOICE). Bipolar Disord., 2015; 17: 212-223
  Google Scholar
• 45. Taylor D., Young C., Mohamed R., Paton C., Walwyn R.: Undiagnosedimpaired fasting glucose and diabetes mellitus amongst inpatientsreceiving antipsychotic drugs. J. Psychopharmacol., 2005;19: 182-186
  Google Scholar
• 46. Teff K.L., Rickels M.R., Grudziak J., Fuller C., Nguyen H.L., RickelsK.: Antipsychotic-induced insulin resistance and postprandial hormonaldysregulation independent of weight gain or psychiatric disease.Diabetes, 2013; 62: 3232-3240
  Google Scholar
• 47. Vancampfort D., Mitchell A.J., De Hert M., Sienaert P., Probst M.,Buys R., Stubbs B.: Type 2 diabetes in patients with major depressivedisorder: A meta-analysis of prevalence estimates and predictors.Depress. Anxiety, 2015; 32: 763-773
  Google Scholar
• 48. van Keulen K., Knol W., Schrijver E.J.M., van Marum R.J., van StrienA.M., Nanayakkara P.W.B.: Prophylactic use of haloperidol and changesin glucose levels in hospitalized older patients. J. Clin. Psychopharmacol.,2018; 38: 51-54
  Google Scholar
• 49. Ward M., Druss B.: The epidemiology of diabetes in psychoticdisorders. Lancet Psychiatry, 2015; 2: 431-451
  Google Scholar
• 50. Weston-Green K., Huang X.F., Deng C.: Second generation antipsychotic-induced type 2 diabetes: A role for the muscarinic M3 receptor.CNS Drugs, 2013; 27: 1069-1080
  Google Scholar
• 51. Zhou X., Ren L., Yu Z., Huang X., Li Y., Wang C.: The antipsychoticssulpiride induces fatty liver in rats via phosphorylation of insulinreceptor substrate-1 at serine 307-mediated adipose tissue insulinresistance. Toxicol. Appl. Pharmacol., 2018; 345: 66-74
  Google Scholar

Full text